Recent studies have reported high rates of reintervention after primary stenting for hepatic artery stenosis (HAS) due to the loss of primary patency. The aims of this study were to evaluate the outcomes of primary stenting after HAS in a large cohort with longterm follow-up. After institutional review board approval, all patients undergoing liver transplantation between 2003 and 2017 at a single institution were evaluated for occurrence of hepatic artery complications. HAS occurred in 37/454 (8%) of patients. HAS was defined as >50% stenosis on computed tomography or digital subtraction angiography. Hepatic arterial patency and graft survival were evaluated at annual intervals. Primary patency was defined as the time from revascularization to imaging evidence of new HAS or reaching a censored event (retransplantation, death, loss to follow-up, or end of study period). Hepatic artery stenosis (HAS) occurs in 4%-10% of liver transplantation patients. (1-3) HAS is considered a risk factor for hepatic artery thrombosis, ischemic biliary complications, graft dysfunction or loss, and death. (4, 5) Percutaneous revascularization of HAS can be performed by either percutaneous balloon angioplasty (PBA) or hepatic arterial stent placement. A meta-analysis reviewing literature on this subject between 1970 and 2011 found no statistical difference between PBA and hepatic artery stenting. (6) More recent studies with larger cohorts and longer follow-up have reported similar results. (7) (8) (9) (10) However, several centers have moved toward primary stent placement. (7, 8) 
remains ambiguous, often because of an inclusion of mixed study populations that include both PBA and stent groups, variable sample size (case series of <10 patients), and variability in technique (including stent type and size differences and poststent anticoagulation). (6) Therefore, additional data, with specific attention to practice compared with existing studies, are required. Similar to others who have reported better outcomes with primary stent placement over PBA, our center has also moved to primary stent placement in clinical practice. Here, we assessed primary technical success, longterm patency, and graft outcomes in patients with critical HAS after liver transplantation treated with primary "intent-to-stent" arterial stent placement.
Patients and Methods
This was an institutional review board-approved, Health Insurance Portability and Accountability Act of 1996-compliant retrospective observational review of all adult patients with a history of liver transplantation that underwent hepatic arteriography (n = 41) at a single tertiary care hospital between 2003 and 2017. At our institution, screening Doppler ultrasound is performed prior to 10:00 am on postoperative days 1, 2, 3, and 7 after transplantation. Most patients had worsening liver function tests (39/41), but 2 patients had abnormal screening Doppler ultrasound without worsening liver function tests in the immediate postoperative period. The absence of intrahepatic flow on Doppler ultrasound (6/41), presence of hepatic artery resistive index <0.5 (27/41), or hepatic artery peak systolic velocities >200 cm/second (3/41) were indications for computed tomography (CT), magnetic resonance, or catheter angiography. In 4/41 patients, Doppler ultrasound examinations were normal, but patients underwent CT angiography because of biopsy evidence of hepatic ischemia (n = 1) or an unexplained 2-to 3-fold elevation in liver enzymes (n = 3). One patient with worsening liver function tests and high surgical suspicion for HAS underwent CT directly without a Doppler ultrasound examination. For patients who underwent CT or magnetic resonance angiography (18/41), hepatic artery luminal narrowing >50% was investigated with catheter angiography.
On the basis of recent literature and institutional experience, our practice is to treat HAS with primary stent placement rather than attempting PBA. Thus, patients who underwent revascularization with PBA (n = 5) and patients with hepatic artery thrombosis (n = 4) were excluded from analysis. Because prior studies have reported more reinterventions occurring early after the index revascularization, 2 patients with <6 months of follow-up due to recent stenting were also excluded. Thus, the final cohort consisted of 30 patients.
Procedures were performed from a femoral (n = 28) or brachial (n = 2) arterial access. A total of 12 interventional radiologists (average time since fellowship, 8 years; range, 0-42 years) performed the procedures. Most procedures (17/30; 57%) were performed by interventional radiologists within 5 years of fellowship Measurements for vessel diameter and stenosis dimensions were performed after the administration of 200 µg of nitroglycerin and 500 units of heparin into the hepatic artery. Stent diameters were intentionally oversized by 1 mm (~15%-20%) compared with the measured diameter in all patients. Stenoses were carefully traversed using a soft hydrophilic wire (Headliner, Terumo Cardiovascular Corp.). A 0.021-inch microcatheter (Renegade STC, Boston Scientific Corp., Boston, MA) was advanced over the wire, and the wire was exchanged for a stiffer wire (Transcend or V18, Boston Scientific Corp.). The microcatheter was then removed, and a 6-Fr-long hydrophilic sheath (Flexor Ansel, Cook Medical, Bloomington, IN) was advanced into the celiac or common hepatic artery. Intravenous heparin (50 mg/kg) was administered prior to revascularization. For stenoses >75%, prestenting balloon angioplasty was performed (n = 11/30, 37%) using 3-or 4-mm balloon catheters when needed to facilitate stent catheter advancement. Poststenting angioplasty up to the rated stent diameter was performed in all patients. All patients received antiplatelet medications starting on the day of the procedure (325 mg of aspirin, loading dose; 300 mg of clopidogrel, loading dose; and then 75 mg of clopidogrel, oral daily for 1 year; and 81 mg of aspirin, oral for life).
Technical success was defined as successful resolution of the hepatic artery narrowing (primary, in 1 procedure; secondary, in >1 procedure). Hepatic arterial patency, graft survival, and mortality were evaluated at annual intervals. Follow-up was censored on December 31, 2017 (date that the last medical record review was performed). Primary patency was defined as the time from revascularization to imaging evidence of new HAS or reaching a censored event (retransplantation, listing for retransplantation, death, loss to follow-up, or end of study period). Primary-assisted patency was defined as time from revascularization to a censored event, including any repeat endovascular treatments (PBA or stenting) for the index lesion.
In statistical analysis, categorical variables are reported as count and percentage. Continuous variables are presented as median with interquartile range (IQR) or average and range. Primary patency was assessed using Kaplan-Meier curve analysis. Statistical analysis was performed using SAS statistical software (SAS version 9.4, SAS Institute Inc., Cary, NC).
Results
HAS occurred in 37/454 (8%) patients (17 female, 46%; age-median, 50 years; range, 27-72 years) who underwent deceased donor liver transplantation during the study period ( Table 1 ). The causes of end-stage liver disease leading to liver transplantation included alcoholic cirrhosis (n = 14, 38%), hepatitis C virus (n = 6, 16%), drug toxicity (n = 4, 11%), nonalcoholic steatotic hepatitis (n = 4, 10%), hepatitis B virus (n = 2, 5%), hepatic artery thrombosis in a previously transplanted liver (n = 2, 5%), primary sclerosing cholangitis (n = 1, 3%), primary biliary cirrhosis (n = 1, 3%), parasitic infection (n = 1, 3%), hepatopulmonary syndrome (n = 1, 3%), and unknown etiology (n = 1, 3%). The 2 patients with hepatic artery thrombosis underwent initial liver transplantation because of primary sclerosing cholangitis and graft-versus-host disease. They presented within 30 days with complete hepatic artery thrombosis detected on noninvasive testing and were relisted for transplantation.
Surgical anastomosis was performed between the common hepatic artery (22/37), proper hepatic artery (7/37), celiac artery (7/37), and splenic artery (1/37) on the donor side and the common hepatic artery (15/37), proper hepatic artery (13/37), infrarenal aorta (3/37), splenic artery (3/37), supraceliac aorta (2/37), and replaced right hepatic artery (1/37) on the recipient side. A branch patch was created in 11/37 (30%) of patients prior to anastomosis. Surgical repair of HAS was attempted in 5/37 (14%) prior to the endovascular intervention.
Patients undergoing revascularization with PBA (n = 5) and with follow-up <6 months after revascularization (n = 2) were excluded. For the 30 patients who underwent primary arterial stent placement with >6-month follow-up, the median interval between liver transplant and HAS diagnosis was 45 days (IQR, 7-112 days). The median interval between liver transplant and hepatic arteriography was 57 days (IQR, 17-115 days). Endovascular treatment was performed within 1 week of liver transplantation in 5/30 (17%), within 30 days in 13/30 (43%), and within 90 days in 19/30 (63%) patients.
Technical success was accomplished in 97% (29/30) of patients. One procedure was unsuccessful due to hepatic artery thrombosis occurring during stent placement. Of the 29 technically successful procedures, there was primary technical success in 27 (93%) patients and secondary technical success in 2 (7%). A total of 39 stents were placed in 30 patients during the study period ( Median follow-up interval was 41 months (IQR, 25-86 months). Four (13%) patients died because of unrelated reasons 3-125 months after the stent placement procedure. Two patients were lost to follow-up (44 and 155 months) after the procedure. Primary patency was 90% at 1 year and remained unchanged throughout the remaining follow-up period (Fig. 1) . Median stent patency was 36 months (range, 11-81 months).
Reintervention was required in 3 patients to maintain stent patency. The median time period between primary stenting and retreatment was 5.9 months NOTE: Data are given as n (%) unless otherwise noted.
FIG. 1.
Kaplan-Meier curves demonstrating primary patency for hepatic arterial stent placement over the study period.
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(range, 4.4-11.1 months). All 3 patients underwent technically successful interventions, and the primaryassisted patency rate was 100%. No patient developed graft dysfunction or hepatic arterial thrombosis, required retransplantation, or was listed for retransplantation after hepatic arterial stent placement. Intraprocedural complications occurred in 1 (3%) procedure: a dislodged undeployed balloon expandable stent that was successfully retrieved without further complication. Only 1 patient had a postprocedure complication (retroperitoneal hematoma, 3%), which required conservative treatment.
Discussion
Although the incidence of HAS after deceased donor liver transplant is overall low (8% in this series), the downstream consequences of unsuccessful treatment can be severe, including artery thrombosis, graft failure, need for retransplantation, or death. (4) Several recent studies on endovascular treatment of HAS using stents have reported improvements in overall outcomes and longterm patency rates over PBA alone. However, even recent stent-based studies report 76%-86% patency rates beyond a year and relatively high reintervention rates of 24%-30%. (7, 11, 12) The largest series of HAS treatment recently reported results on 99 patients who underwent PBA (n = 34) or stent placement (n = 65). (11) However, the reintervention rate in this study was also high (38% for PBA and 22% for stenting) and most reinterventions occurred within 6 months of the index treatment. Major complication rates are lower in more recent studies, but still significant, ranging from as low as 7.5%-33%. (8, 11, 12) This may be why several authors have questioned the need for hepatic arterial revascularization after liver transplantation, especially in asymptomatic patients. (9, 13, 14) In this study, we report high primary patency (90%), excellent primary-assisted patency (100%), and low reintervention rates (10%) after primary stent placement for HAS after liver transplantation.
Although early studies reported no difference in PBA compared with primary stent placement for HAS, more recent literature has demonstrated significantly higher primary patency rates (78% versus 0%) and longer time to reintervention with primary stenting (51 versus 106 days). (15) Clearly, there has been refinement based on technique, as demonstrated in the meta-analysis by Rostambeigi et al., in which recent study publication year was the only factor significantly associated with lower retransplantation rates-attributed to improvement in endovascular techniques. (6) Several factors may contribute to our high reported rates of primary patency and very low rates of reintervention without need for nonendovascular salvage therapy. First, patients in the current study routinely received intra-arterial nitroglycerin and heparin prior to stent placement, which may have implications for appropriate size measurement for stent selection by preventing intrahepatic thrombus or vasospasm. This technique was first reported by Mondragon et al., but no study since then has explicitly mentioned the use of both medications prior to revascularization. (6, 16) Second, we have routinely used an approach in which stents were slightly oversized to the target artery before and after the stenotic lesion (artery + 1 mm approach, or approximately 15%-20% larger), which may also contribute to higher longterm patency rates. No arterial dissection or rupture was observed in our cohort by using this approach. Third, since 2010, we have routinely used cone beam CT angiography to help in planning for revascularization, including anatomy of the stenosis, vessel measurements, and optimal image intensifier angles for visualizing the stenosis during traversal and revascularization. Although vessel tortuosity is often the primary determinant for endovascular procedural success or complications, utilization of cone beam CT angiography improves procedural planning and success in patients with tortuous vessels, in our experience.
Finally, our entire cohort received a loading dose of aspirin and clopidogrel immediately after revascularization followed by a maintenance dose for 1 year after stenting. Thus, intra-arterial anticoagulation and postprocedural antiplatelet medications may be critical in improving patency and reducing reintervention rates of primary stenting. Other groups have used 1 month or 3-6 months of dual antiplatelet therapy after hepatic arterial stent placement. (7, 11) Optimal antiplatelet regimens have not been established for this particular group of patients. Given the high risk to the graft within the first 12 months after transplant from an HAS, we have chosen to prolong the antiplatelet therapy beyond 3 months anticipating that any competing risk from medication-related bleeding will be very low. Although conventional postintervention time frames for dual antiplatelet medication use is up to 1 year, this practice is based on coronary artery and peripheral vascular interventions and may not be completely applicable to this posttransplant cohort based on differences in vessel sensitivity/reaction to implanted stents, the pathophysiology of atherosclerotic disease reoccurrence in coronary or peripheral arteries, and propensity for localized intimal fibrosis or inflammation in patients on immunosuppressive therapies. Therefore, longer periods of antiplatelet agents may contribute to the longterm high rates of stent patency reported here.
Recent studies of hepatic arterial stenting for HAS report intentional exclusion of certain patients with HAS to reduce the risk of arterial rupture: One study referred patients with HAS within 1 week of transplantation to surgical revision, whereas a second study reported an institutional policy to avoid treating HAS of <21 days after liver transplantation. (8, 12) Arterial rupture appears to be more common with PBA, occurring in 6%-12% of patients. (7, (17) (18) (19) Such complications are not commonly reported in any recent study of primary stent placement, including this study. (7) (8) (9) 12) Early surgical revision has a reported technical success rate of 78% with hepatic artery occlusion occurring in 23% of patients. (3) In comparison, a significant proportion of the patients in this study presented in the early postoperative period-17% of patients presented within 1 week of the surgical anastomosis (43% within 30 days), which is when the artery may be most prone to dissection or rupture. In all of these cases, primary hepatic arterial stent placement was technically successful. Thus, continued improvement in the endovascular technique may result in primary stent placement as the treatment of choice for HAS even in the perioperative period after liver transplantation.
One of the strengths of this study is that 12 different operators (>50% within 5 years of fellowship) performed all procedures, which indicates the relative importance of institutional rather than operator experience in our reported outcomes (compared with the other largest series, where a single operator performed all cases). (7) We have described our technique in the Patients and Methods section. Although it is often difficult to replicate the results of single-center studies, the diverse set of operators of varying experience levels suggests that the reported technique and results may be reproducible in a real-world interventional practice.
A meta-analysis by Rostambeigi et al. summarized the results of studies published between 1970 and 2011 that found no significant differences in outcomes for PBA and stenting of HAS for procedural success (89% versus 98%), complications (16% versus 19%), arterial patency at 6-31 months (76% versus 86%), and reintervention rate (22% versus 25%). (6) However, 16 out of 26 studies pooled by Rostambeigi et al. were case reports or case series with <10 patients. Since 2011, larger studies evaluating endovascular treatment of HAS have demonstrated an increasing propensity for primary stent placement rather than PBA. (7, 8, 12) For example, Sommacale et al. reported that 65% of patients undergoing primary stenting did not require reintervention and the time to reintervention was 170 days. (12) Thus, our study adds to the growing literature that supports primary stenting for HAS as safe, efficacious, and having excellent longterm outcomes compared with PBA.
There are several limitations to our study. It is retrospective, at a single institution, and, although the number of patients included is similar to the largest currently reported series, the sample size is relatively small. There is a lack of a control group because typical practice at our institution is to perform primary stenting for HAS. Therefore, results could only be compared with published literature rather than being directly compared with PBA.
In conclusion, primary stent placement for HAS results in high longterm primary patency rates with low reintervention rates. We report the usefulness of several endovascular techniques that may result in improved outcomes and demonstrated that primary stenting for HAS is feasible in the early posttransplantation period. These findings add to increasing evidence that primary stenting is a superior option for treatment of HAS after liver transplantation.
